Pancreatic cancer vaccine shows promise in first human trial, preventing disease in high-risk patients

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. Mutual Fund and ETF data provided by LSEG. Fox News senior correspondent Jonathan Serrie reports on doctors seeing results from Daraxonrasib, a new drug targeting pancreatic cancer, on ‘Special Report.’ A new vaccine for the prevention of pancreatic cancer has shown promise in an early study at Johns Hopkins School of Medicine in Baltimore, Maryland. A phase 1 trial published in Cancer Discovery, a journal of the American Association for Cancer Research, tested an experimental vaccine called mKRAS-VAX in 20 people, according to a press release. Participants had an inherited risk of pancreatic ductal adenocarcinoma (PDAC), the most common and aggressive form of pancreatic cancer, along with an abnormality detected in imaging, typically a pancreatic cyst. These individuals had not been diagnosed with pancreatic cancer. NEW PANCREATIC CANCER PILL NEARLY DOUBLES SURVIVAL TIME IN BREAKTHROUGH TRIA